BAY 58-2667 . hydrochloride
| Code | Size | Price |
|---|
| AG-CR1-3509-M001 | 1 mg | £85.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Cinaciguat . hydrochloride
Appearance:
White solid.
CAS:
646995-35-9
EClass:
32160000
Form (Short):
solid
InChi:
InChI=1S/C36H39NO5.ClH/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28;/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41);1H
InChiKey:
LLHMBJOVHATVSP-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 646995-35-9. Formula: C36H39NO5 . HCl . 0.5H2O. MW: 565.6 . 36.5 . 9.0. Nitric oxide (NO)- and heme-independent soluble guanylyl cyclase activator. Shows potent cardiovascular effects. Improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Exhibits potent vasodilator and antiplatelet activity. Anti-aggregating agent.
MDL:
MFCD28127267
Molecular Formula:
C36H39NO5 . HCl . 0.5H2O
Molecular Weight:
565.6 . 36.5 . 9.0
Package Type:
Vial
Product Description:
Nitric oxide (NO)- and heme-independent soluble guanylyl cyclase activator. Shows potent cardiovascular effects. Improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Exhibits potent vasodilator and antiplatelet activity. Anti-aggregating agent.
Purity:
>98% (NMR)
SMILES:
Cl.OC(=O)CCCCN(CCC1=C(OCC2=CC=C(CCC3=CC=CC=C3)C=C2)C=CC=C1)CC1=CC=C(C=C1)C(O)=O
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle: J.P. Stasch, et al.; Br. J. Pharmacol. 136, 773 (2002) | Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase: P. Schmidt, et al.; Eur. J. Pharmacol. 468, 167 (2003) | Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease: G. Boerrigter & JC. Burnett Jr.; Cardiovasc. Drug Rev. 25, 30 (2007) (Review) | Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers: R. Frey, et al.; J. Clin. Pharmacol. 48, 1400 (2008) | BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts: T. Krieg, et al.; Eur. Heart J. 30, 1607 (2009) | Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure: H. Lapp, et al.; Circulation 119, 2781 (2009) | Role of guanylate cyclase modulators in decompensated heart failure: V. Mitrovic, et al.; Heart Fail. Rev. 14, 309 (2009) (Review) | Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure: J. Tamargo, et al.; Curr. Opin. Investig. Drugs 11, 1039 (2010) | Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase: S. Roger, et al.; Vascul. Pharmacol. 53, 281 (2010) | Transgenic mice for real time visualization of cGMP in intact adult cardiomyocytes: K. Götz, et al.; Circ. Res. 114, 1235 (2014) | Soluble Guanylate Cyclase as a Novel Treatment Target for Osteoporosis: J. Joshua, et al. Endocrinology 155, 4720 (2014) | Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice: M.G. de Oliveira, et al.; Am. J. Physiol. Renal Physiol. 311, F85 (2016)